{"id":"kps-0373-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperthermia or altered temperature sensation"},{"rate":null,"effect":"Gastrointestinal effects"}]},"_chembl":{"chemblId":"CHEMBL4297622","moleculeType":"Small molecule","molecularWeight":"366.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TRPV1 is a key ion channel involved in nociception and pain transmission. By antagonizing TRPV1, KPS-0373 reduces the activation of pain-sensing neurons, thereby decreasing pain signal propagation to the central nervous system. This mechanism is being explored for chronic pain conditions where TRPV1 plays a significant role.","oneSentence":"KPS-0373 is a selective TRPV1 antagonist that blocks pain signaling through the transient receptor potential vanilloid 1 channel.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:56.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT01970098","phase":"PHASE3","title":"A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-10-09","conditions":"Spinocerebellar Degeneration","enrollment":374},{"nctId":"NCT01970137","phase":"PHASE3","title":"A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01970111","phase":"PHASE3","title":"An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01970124","phase":"PHASE3","title":"A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":135054,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KPS-0373, High dose","genericName":"KPS-0373, High dose","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KPS-0373 is a selective TRPV1 antagonist that blocks pain signaling through the transient receptor potential vanilloid 1 channel. Used for Chronic pain (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}